Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved the primary and all key secondary endpoints, including demonstrating improvements in a number of cardiovascular risk factors With these results, Lilly is on track to submit orforglipron to global regulatory agencies by year-end and is making substantial investments to meet anticipated demand at launch 1 "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," said In the ATTAIN-1 trial, orforglipron met the primary endpoint of superior body weight reduction compared to placebo
Testing reveals whether you have genetic predispositions toward higher or lower baseline appetite and metabolic efficiency, helping PlexusDx tailor dosing and nutritional guidance for your unique peptide pathways
This commitment reflects PlexusDx's belief that safe weight loss should never be compromised by fear of escalating drug costs
Retrieved 1 September 2015
This risk-based approach to lab requirements balances thoroughness with accessibility
US$ 21.49
US$ 28.77
US$ 22.89
US$ 21.52
US$ 29.55
US$ 21.82
US$ 27.87
